Tenofovir (TDF) and Emtricitabine (FTC) ( DrugBank: Emtricitabine, Tenofovir )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 325 | Hereditary autoinflammatory syndrome | 1 |
325. Hereditary autoinflammatory syndrome
Clinical trials : 7 / Drugs : 16 - (DrugBank : 6) / Drug target genes : 2 - Drug target pathways : 35
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03304717 (ClinicalTrials.gov) | December 2022 | 4/8/2017 | Reverse Transcriptase Inhibitors in Aicardi Goutières Syndrome | Reverse Transcriptase Inhibitors in Aicardi Goutières Syndrome | Aicardi Goutières Syndrome | Drug: Tenofovir (TDF) and Emtricitabine (FTC);Other: Placebo | Children's Hospital of Philadelphia | National Institutes of Health (NIH);Emerson Resources;Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);National Human Genome Research Institute (NHGRI);Gilead Sciences | Not yet recruiting | 2 Years | 18 Years | All | 34 | Phase 1/Phase 2 | United States |